Abstract: A method and an X-ray apparatus generate a projective X-ray representation of an examination object. Two projective images obtained from a phase contrast measurement are adapted to each other in respect of their representation format and a result image is generated by combining the adapted images. The result image allows extensive separation of different structures in the examination object that is used.

Abstract: A method and an x-ray apparatus for interferometric 2D x-ray imaging, use a Talbot-Lau interferometer having at least one phase grating and an analysis grating for producing 2D images of an object to be examined using a phase stepping method. A stepwise readout of a detector is carried out continuously at a multiplicity of the phase positions of an interference pattern. Time sequences of readout interval data records which overlap in time are extracted from the readout data records, and at least one result image data record is calculated from an absorption image and/or a phase-contrast image and/or a dark-field image from each readout interval data record.

Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.

Abstract: An implant to fill a hole in tissue, such as bone tissue, comprising a first portion that is insertable through the hole when in a first compressed position, wherein the first portion cannot pass through the hole when in a first deployed position; and a second portion that cannot pass through the hole when in the second deployed position. The first and second portions of the implant can be deployed independently. Therefore, in operation, it is possible to insert the first portion of the implant through the hole when in the first compressed position, deploying the first portion to transition it to the first deployed position while the second portion remains in the second compressed position, and then deploying the second portion to transition it to the second deployed position. The devices and methods may be used, for example, in transsphenoidal or other orthopedic surgeries involving bone tissue.

Abstract: A cranial burr hole plate is provided, the burr hole plate comprising a plate body and a plurality of spikes extending from the plate body. The spikes are configured to engage cranial bone, wherein the burr hole plate is deformable to enable movement of the spikes from a burr hole disengaging configuration to a burr hole engaging configuration upon deformation of the burr hole plate. Also provided is a deformation instrument for moving the spikes of a cranial burr hole plate into the burr hole engaging configuration is provided. Moreover, a cranial burr hole plating system is provided that comprises the cranial burr hole plate and the deformation instrument.

Abstract: The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.

Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.

Abstract: A method and an X-ray apparatus generate a projective X-ray representation of an examination object. Two projective images obtained from a phase contrast measurement are adapted to each other in respect of their representation format and a result image is generated by combining the adapted images. The result image allows extensive separation of different structures in the examination object that is used.

Abstract: A mobile grating-detector arrangement has an X-ray detector and at least one grating. The grating-detector arrangement is configured to record an interferometric X-ray image of at least one body part of a patient in a patient bed in operation. In addition, an X-ray system with such a grating-detector arrangement and its use for X-ray interferometric imaging is described.

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Abstract: A method and an x-ray apparatus for interferometric 2D x-ray imaging, use a Talbot-Lau interferometer having at least one phase grating and an analysis grating for producing 2D images of an object to be examined using a phase stepping method. A stepwise readout of a detector is carried out continuously at a multiplicity of the phase positions of an interference pattern. Time sequences of readout interval data records which overlap in time are extracted from the readout data records, and at least one result image data record is calculated from an absorption image and/or a phase-contrast image and/or a dark-field image from each readout interval data record.

Abstract: The present invention provides methods for treating and preventing viral disease in farmed fish. In particular, the present invention relates to compositions and methods for improving heart health in farmed salmon.

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Abstract: A power tool, includes an electrical motor unit connectable to a battery unit, wherein: a step-up converter, connectable between the battery unit and electrical motor unit, converts a battery voltage Ubattery provided by the battery unit to a higher step-up voltage Ustep-up, and provides Ustep-up to the electrical motor unit as an output voltage Uoutput; a bypass circuit, arranged in parallel with the step-up converter, connects the battery unit to and provides Ubattery to the electrical motor unit as Uoutput; and at least one control unit is arranged to control the step-up converter and the bypass circuit, such that Uoutput can switch between Ubattery and Ustep-up, based on tool related parameters, including Uoutput, an output current Ioutput provided to the motor, a rotational speed ?motor of the motor unit multiplied with a torque T provided by the tool, and an output power Poutput provided to the electrical motor unit.

Abstract: The present disclosure is drawn to a method of administering glyburide intravenously to a subject over a period of time as a first bolus administration of glyburide; a second bolus administration of glyburide, after the first bolus; and a first continuous infusion administration of glyburide, wherein the first continuous infusion is administered at a first rate of administration for a first period of time, after the second bolus administration of glyburide.

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Abstract: The present disclosure is drawn to a method of administering glyburide intravenously to a subject over a period of time as a first bolus administration of glyburide; a second bolus administration of glyburide, after the first bolus; and a first continuous infusion administration of glyburide, wherein the first continuous infusion is administered at a first rate of administration for a first period of time, after the second bolus administration of glyburide.